612 related articles for article (PubMed ID: 29850873)
1. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
[TBL] [Abstract][Full Text] [Related]
2. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
[TBL] [Abstract][Full Text] [Related]
3. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Sandborn WJ; Peyrin-Biroulet L; Sharara AI; Su C; Modesto I; Mundayat R; Gunay LM; Salese L; Sands BE
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Bressler B; Francisconi C; Vermeire S; Lawendy N; Salese L; Sawyerr G; Shi H; Su C; Judd DT; Jones T; Loftus EV
Inflamm Bowel Dis; 2023 Jan; 29(1):27-41. PubMed ID: 36342120
[TBL] [Abstract][Full Text] [Related]
7. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
Colombel JF
Inflamm Bowel Dis; 2018 Sep; 24(10):2173-2182. PubMed ID: 29788127
[TBL] [Abstract][Full Text] [Related]
8. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R
Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S
Aliment Pharmacol Ther; 2019 Nov; 50(10):1068-1076. PubMed ID: 31599001
[TBL] [Abstract][Full Text] [Related]
10. Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective.
Caldera F; Hayney MS; Cross RK
Inflamm Bowel Dis; 2019 May; 25(6):955-957. PubMed ID: 30605536
[No Abstract] [Full Text] [Related]
11. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
[TBL] [Abstract][Full Text] [Related]
12. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
[TBL] [Abstract][Full Text] [Related]
13. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
[TBL] [Abstract][Full Text] [Related]
14. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
[TBL] [Abstract][Full Text] [Related]
15. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Sands BE; Colombel JF; Ha C; Farnier M; Armuzzi A; Quirk D; Friedman GS; Kwok K; Salese L; Su C; Taub PR
Inflamm Bowel Dis; 2021 May; 27(6):797-808. PubMed ID: 32870265
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C
J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746
[TBL] [Abstract][Full Text] [Related]
18. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.
Sands BE; Long MD; Reinisch W; Panés J; Loftus EV; Nduaka CI; Soonasra A; Mundayat R; Lawendy N; Chan G; Friedman GS; Su C
Inflamm Bowel Dis; 2022 Feb; 28(2):234-245. PubMed ID: 33742652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
